| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Animal: DNA Viruses |
Institut für Klinische und Molekulare Virologie, Universität Erlangen-Nürnberg, Schlossgarten 4, 91054 Erlangen, Germany1
Axxima Pharmaceuticals AG, Martinsried, Germany2
Author for correspondence: Manfred Marschall. Fax +49 9131 85 26493. e-mail manfred.marschall{at}viro.med.uni-erlangen.de
The protein kinase pUL97, encoded by human cytomegalovirus (HCMV), is an important determinant of virus replication. Recently, indolocarbazoles were identified as a class of substances that inhibit the pUL97 kinase activity in vitro. In parallel, it was shown that indolocarbazoles interfere with HCMV replication; however, the causal relationship between inhibition of pUL97 kinase activity and virus replication has not been clarified. Here evidence is provided that indolocarbazole-mediated inhibition of virus replication is a direct result of diminished pUL97 protein kinase activity. In cell culture infections, a strong and selective antiviral activity was measured with respect to several strains of HCMV in contrast with other related or non-related viruses. For fine quantification, recombinant HCMVs expressing green fluorescent protein were used, demonstrating the high sensitivity towards compounds NGIC-I and Gö6976. Interestingly, a ganciclovir-resistant virus mutant (UL97-M460I) showed increased sensitivity to both compounds. Supporting this concept, transfection experiments with cloned pUL97 revealed that ganciclovir-resistant mutants were characterized by reduced levels of autophosphorylation compared with wild-type and possessed particularly high sensitivity to indolocarbazoles. Moreover, the Epstein–Barr virus-encoded homologous kinase, BGLF4, which showed a similar pattern of autophosphorylation and ganciclovir phosphorylation activities, was not inhibited. Importantly, a cytomegalovirus deletion mutant, lacking a functional UL97 gene and showing a severe impairment of replication, was completely insensitive to indolocarbazoles. Thus, our findings indicate that a specific block in the activity of pUL97 is the critical step in indolocarbazole-mediated inhibition of virus replication and that pUL97 might be targeted very efficiently by a novel antiviral therapy.
This article has been cited by other articles:
|
|
 |
|
  J. Milbradt, S. Auerochs, and M. Marschall Cytomegaloviral proteins pUL50 and pUL53 are associated with the nuclear lamina and interact with cellular protein kinase C J. Gen. Virol., October 1, 2007; 88(10): 2642 - 2650. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Gershburg, S. Raffa, M. R. Torrisi, and J. S. Pagano Epstein-Barr Virus-Encoded Protein Kinase (BGLF4) Is Involved in Production of Infectious Virus J. Virol., May 15, 2007; 81(10): 5407 - 5412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Schregel, S. Auerochs, R. Jochmann, K. Maurer, T. Stamminger, and M. Marschall Mapping of a self-interaction domain of the cytomegalovirus protein kinase pUL97 J. Gen. Virol., February 1, 2007; 88(2): 395 - 404. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Ehlers, G. Dural, M. Marschall, V. Schregel, M. Goltz, and J. Hentschke Endotheliotropic elephant herpesvirus, the first betaherpesvirus with a thymidine kinase gene. J. Gen. Virol., October 1, 2006; 87(Pt 10): 2781 - 2789. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. N. Prichard, W. J. Britt, S. L. Daily, C. B. Hartline, and E. R. Kern Human Cytomegalovirus UL97 Kinase Is Required for the Normal Intranuclear Distribution of pp65 and Virion Morphogenesis J. Virol., December 15, 2005; 79(24): 15494 - 15502. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Gershburg and J. S. Pagano Epstein-Barr virus infections: prospects for treatment J. Antimicrob. Chemother., August 1, 2005; 56(2): 277 - 281. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Yue, E. Gershburg, and J. S. Pagano Hyperphosphorylation of EBNA2 by Epstein-Barr Virus Protein Kinase Suppresses Transactivation of the LMP1 Promoter J. Virol., May 1, 2005; 79(9): 5880 - 5885. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Mett, K. Holscher, H. Degen, C. Esdar, B. F. De Neumann, B. Flicke, T. Freudenreich, G. Holzer, S. Schinzel, T. Stamminger, et al. Identification of Inhibitors for a Virally Encoded Protein Kinase by 2 Different Screening Systems: In Vitro Kinase Assay and In-Cell Activity Assay J Biomol Screen, February 1, 2005; 10(1): 36 - 45. [Abstract] [PDF]
|
|
|
|
|
|
E. Gershburg, M. Marschall, K. Hong, and J. S. Pagano Expression and Localization of the Epstein-Barr Virus-Encoded Protein Kinase J. Virol., November 15, 2004; 78(22): 12140 - 12146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Herget, M. Freitag, M. Morbitzer, R. Kupfer, T. Stamminger, and M. Marschall Novel Chemical Class of pUL97 Protein Kinase-Specific Inhibitors with Strong Anticytomegaloviral Activity Antimicrob. Agents Chemother., November 1, 2004; 48(11): 4154 - 4162. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Gershburg, K. Hong, and J. S. Pagano Effects of Maribavir and Selected Indolocarbazoles on Epstein-Barr Virus Protein Kinase BGLF4 and on Viral Lytic Replication Antimicrob. Agents Chemother., May 1, 2004; 48(5): 1900 - 1903. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Eickhoff, M. Hanke, M. Stein-Gerlach, T. P. Kiang, K. Herzberger, P. Habenberger, S. Muller, B. Klebl, M. Marschall, T. Stamminger, et al. RICK Activates a NF-{kappa}B-dependent Anti-human Cytomegalovirus Response J. Biol. Chem., March 5, 2004; 279(10): 9642 - 9652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Roychowdhury, R. Peng, R. A. Baiocchi, D. Bhatt, S. Vourganti, J. Grecula, N. Gupta, C. F. Eisenbeis, G. J. Nuovo, W. Yang, et al. Experimental Treatment of Epstein-Barr Virus-associated Primary Central Nervous System Lymphoma Cancer Res., March 1, 2003; 63(5): 965 - 971. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
